Form 4: Maze Therapeutics Exec Sells Shares After Option Exercise

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised options and sold 15,000 shares of common stock under a Rule 10b5-1 plan.

Summary

• Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., executed transactions on February 2, 2026, under a pre-arranged Rule 10b5-1 trading plan.
• Bernstein exercised stock options to acquire 15,000 shares of Maze Therapeutics common stock at an exercise price of $10.42 per share.
• Immediately following the option exercise, Bernstein sold all 15,000 acquired shares in multiple transactions.
• The sales occurred at weighted average prices ranging from $44.205 to $47.23 per share.
• After these transactions, Bernstein's direct beneficial ownership of common stock is 0 shares, while beneficial ownership of derivative securities (stock options) stands at 297,407.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While an executive selling shares might typically be seen as negative, the significant profit realized from the option exercise and the execution under a pre-planned 10b5-1 plan mitigate concerns, suggesting a routine monetization of compensation rather than a lack of confidence.

Positives

• The executive realized a significant gain by selling shares at prices substantially higher than the option exercise price of $10.42, indicating a strong appreciation in Maze Therapeutics' stock value.
• The transactions were conducted under a Rule 10b5-1 trading plan, adopted on September 29, 2025, which suggests a pre-planned, non-discretionary sale rather than a reactive decision based on new information.

Negatives

• The executive's direct beneficial ownership of common stock was reduced to 0 shares following these transactions, which could be interpreted by some as a reduction in direct equity alignment with shareholders, although it is common for executives to diversify or monetize vested options.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the scheduled nature of the Rule 10b5-1 plan and the vesting schedule of the remaining options.

Industry Context

StockSavvy.ai notes that executive 'exercise and sell' transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors. These transactions often reflect executives monetizing vested equity compensation and managing personal finances, rather than signaling a change in company fundamentals. The significant spread between the exercise price and sale price suggests a healthy stock performance for Maze Therapeutics leading up to the transaction date.

Comparison to Industry Standards

• This type of 'exercise and sell' transaction is a standard practice for executives in publicly traded companies, particularly in high-growth sectors like biotech, to realize gains from vested stock options. For example, similar transactions are frequently observed at companies like Moderna (MRNA) or BioNTech (BNTX) where executives monetize equity compensation after periods of significant stock appreciation.
• The use of a Rule 10b5-1 plan aligns with best practices for insider trading compliance, providing an affirmative defense against claims of trading on material non-public information. This is a common governance standard across the S&P 500.

Stakeholder Impact

• Shareholders: The sale by a key executive could lead to minor short-term sentiment shifts, but the pre-planned nature and profit realization are generally neutral to slightly positive, reflecting stock appreciation.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The remaining 297,407 derivative securities (stock options) will continue to vest monthly as per the original schedule, subject to the reporting person's continued service to the Issuer.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned executive transaction (exercise and sell) under a Rule 10b5-1 plan. While the executive realized substantial gains, which is a positive indicator of past stock performance, the transaction itself does not provide new fundamental information about Maze Therapeutics' future prospects or operations that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, as the filing confirms a scheduled event rather than signaling a new directional catalyst.

Keywords

Maze Therapeutics, MAZE, Harold Bernstein, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Executive Compensation